Bio View (BIOV.TA) Stock Price

Bio View Price

TASE·CLOSED
90.30ILS-3.40 (-3.70 %)
Market closed

Over the last 19 years Bio View grew revenue by 3.9% annually, reaching 25.66 M ILS. Earnings per share have declined at 21.9% per year over the last 14 years. For Bio View, the net margin of -12.3% is down versus 3.4% a few years ago. At today's price the dividend yield works out to roughly 0.22%. The stock trades about 2% above its 52-week low.

Bio View stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bio View over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bio View stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bio View's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bio View Stock Price History
DateBio View Price
7/10/202690.30 ILS
7/9/202693.70 ILS
7/8/202694.20 ILS
7/7/202694.30 ILS
7/6/2026101.60 ILS
7/3/202697.90 ILS
7/2/202696.40 ILS
7/1/202693.20 ILS
6/30/202688.30 ILS
6/29/202690.40 ILS
6/26/202690.30 ILS
6/25/202689.70 ILS
6/24/202692.60 ILS
6/23/202694.10 ILS
6/22/202699.10 ILS
6/19/2026112.20 ILS
6/18/2026121.20 ILS
6/17/2026113.60 ILS
6/16/2026109.40 ILS
6/15/2026103.20 ILS
6/12/2026109.20 ILS
6/11/2026113.20 ILS
6/10/2026131.10 ILS
6/9/2026131.80 ILS
6/8/2026128.00 ILS
6/5/2026127.00 ILS
6/4/2026115.90 ILS
6/3/2026120.70 ILS
6/2/2026131.30 ILS
6/1/2026131.30 ILS
5/29/2026119.00 ILS
5/28/2026127.00 ILS
5/27/2026126.00 ILS
5/26/2026132.00 ILS
5/25/2026137.00 ILS
5/22/2026137.00 ILS
5/21/2026137.00 ILS
5/20/2026137.00 ILS
5/19/2026148.00 ILS
5/18/2026147.00 ILS
5/15/2026141.00 ILS
5/14/2026141.00 ILS
5/13/2026150.00 ILS
5/12/2026161.00 ILS
5/11/2026161.00 ILS
5/8/2026161.00 ILS
5/7/2026161.00 ILS
5/6/2026161.00 ILS
5/5/2026161.00 ILS
5/4/2026161.00 ILS
5/1/2026160.00 ILS
4/30/2026164.00 ILS
4/29/2026162.00 ILS
4/28/2026161.00 ILS
4/27/2026161.00 ILS
4/24/2026161.00 ILS
4/23/2026161.00 ILS
4/22/2026160.00 ILS
4/21/2026160.00 ILS
4/20/2026160.00 ILS
4/17/2026163.00 ILS
4/16/2026164.00 ILS
4/15/2026165.00 ILS
4/14/2026160.00 ILS
4/13/2026145.00 ILS
4/10/2026149.00 ILS
4/9/2026163.00 ILS
4/6/2026165.00 ILS
4/3/2026141.00 ILS
3/31/2026141.00 ILS
3/30/2026141.00 ILS
3/27/2026149.00 ILS
3/26/2026152.00 ILS
3/25/2026153.00 ILS
3/24/2026158.00 ILS
3/23/2026160.00 ILS
3/20/2026158.00 ILS
3/19/2026163.00 ILS
3/18/2026161.00 ILS
3/17/2026172.00 ILS
3/16/2026160.00 ILS
3/13/2026167.00 ILS
3/12/2026167.00 ILS
3/11/2026167.00 ILS
3/10/2026164.00 ILS
3/9/2026170.00 ILS
3/6/2026171.00 ILS
3/5/2026163.00 ILS
3/4/2026162.00 ILS
3/2/2026161.00 ILS
2/27/2026169.00 ILS
2/26/2026156.00 ILS
2/25/2026159.00 ILS
2/24/2026165.00 ILS
2/23/2026179.00 ILS
2/20/2026173.00 ILS
2/19/2026169.00 ILS
2/18/2026167.00 ILS
2/17/2026167.00 ILS
2/16/2026170.00 ILS
2/13/2026173.00 ILS
2/12/2026181.00 ILS
2/11/2026181.00 ILS
2/10/2026172.00 ILS
2/9/2026180.00 ILS
2/6/2026176.00 ILS
2/5/2026170.00 ILS
2/4/2026179.00 ILS
2/3/2026180.00 ILS
2/2/2026179.00 ILS
1/30/2026175.00 ILS
1/29/2026175.00 ILS
1/28/2026175.00 ILS
1/27/2026176.00 ILS
1/26/2026176.00 ILS
1/23/2026164.00 ILS
1/22/2026170.00 ILS
1/21/2026176.00 ILS
1/20/2026175.00 ILS
1/19/2026175.00 ILS
1/16/2026186.00 ILS
1/15/2026185.00 ILS
1/14/2026183.00 ILS
1/13/2026189.00 ILS
1/12/2026189.00 ILS
1/9/2026195.00 ILS
1/8/2026192.00 ILS
1/7/2026194.00 ILS
1/6/2026199.00 ILS
1/5/2026178.00 ILS
1/1/2026175.00 ILS
12/31/2025167.00 ILS
12/30/2025150.00 ILS
12/29/2025157.00 ILS
12/25/2025160.00 ILS
12/24/2025160.00 ILS
12/23/2025158.00 ILS
12/22/2025153.00 ILS
12/18/2025159.00 ILS
12/17/2025159.00 ILS
12/16/2025153.00 ILS
12/15/2025154.00 ILS
12/11/2025154.00 ILS
12/10/2025154.00 ILS
12/9/2025160.00 ILS
12/8/2025154.00 ILS
12/4/2025160.00 ILS
12/3/2025160.00 ILS
12/2/2025160.00 ILS
12/1/2025160.00 ILS
11/27/2025160.00 ILS
11/26/2025160.00 ILS
11/25/2025159.00 ILS
11/24/2025159.00 ILS
11/20/2025160.00 ILS
11/19/2025156.00 ILS
11/18/2025146.00 ILS
11/17/2025141.00 ILS
11/13/2025138.00 ILS
11/12/2025140.00 ILS
11/11/2025144.00 ILS
11/10/2025143.00 ILS
11/6/2025143.00 ILS
11/5/2025140.00 ILS
11/4/2025147.00 ILS
11/3/2025147.00 ILS
10/30/2025154.00 ILS
10/29/2025148.00 ILS
10/28/2025160.00 ILS
10/27/2025169.00 ILS
10/23/2025191.00 ILS
10/22/2025198.00 ILS
10/21/2025198.00 ILS
10/20/2025196.00 ILS
10/16/2025196.00 ILS
10/15/2025179.00 ILS
10/9/2025164.00 ILS
10/8/2025164.00 ILS
9/30/2025172.00 ILS
9/29/2025168.00 ILS
9/25/2025189.00 ILS
9/18/2025200.00 ILS
9/17/2025217.00 ILS
9/16/2025218.00 ILS
9/15/2025215.00 ILS
9/11/2025212.00 ILS
9/10/2025205.00 ILS
9/9/2025196.00 ILS
9/8/2025196.00 ILS
9/4/2025205.00 ILS
9/3/2025215.00 ILS
9/2/2025216.00 ILS
9/1/2025215.00 ILS
8/28/2025213.00 ILS
8/27/2025220.00 ILS
8/26/2025229.00 ILS
8/25/2025228.00 ILS
8/21/2025233.00 ILS
8/20/2025231.00 ILS
8/19/2025242.00 ILS
8/18/2025241.00 ILS
8/14/2025233.00 ILS
8/13/2025234.00 ILS
8/12/2025232.00 ILS
8/11/2025229.00 ILS
8/7/2025223.00 ILS
8/6/2025218.00 ILS
8/5/2025234.00 ILS
8/4/2025256.00 ILS
7/31/2025256.00 ILS
7/30/2025256.00 ILS
7/29/2025257.00 ILS
7/28/2025260.00 ILS
7/24/2025252.00 ILS
7/23/2025251.00 ILS
7/22/2025255.00 ILS
7/21/2025239.00 ILS
7/17/2025233.00 ILS
7/16/2025215.00 ILS
7/15/2025226.00 ILS
7/14/2025228.00 ILS
Access this data via the Eulerpool API
Get Free API Key

Bio View Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
27.76 M ILS
-1.41 M ILS
-1.25 M ILS
Jan 1, 2018
25.28 M ILS
-1.77 M ILS
-1.85 M ILS
Jan 1, 2019
35.79 M ILS
3.62 M ILS
2.53 M ILS
Jan 1, 2020
25.96 M ILS
1.43 M ILS
884,000.00 ILS
Jan 1, 2021
30.51 M ILS
3.15 M ILS
2.18 M ILS
Jan 1, 2022
29.15 M ILS
1.96 M ILS
587,000.00 ILS
Jan 1, 2023
34.77 M ILS
1.29 M ILS
383,000.00 ILS
Jan 1, 2024
25.66 M ILS
-2.48 M ILS
-3.15 M ILS

Bio View Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 11, 2026, 6:08 PM
 
REVENUEM ILS
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM ILS
NET INCOMEM ILS
NET INCOME GROWTH%
DIV.ILS
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
22.0025.0026.0026.0023.0030.0034.0033.0027.0025.0035.0025.0030.0029.0034.0025.00
22.2213.644.00–-11.5430.4313.33-2.94-18.18-7.4140.00-28.5720.00-3.3317.24-26.47
59.0960.0065.3865.3860.8763.3361.7663.6459.2656.0057.1460.0056.6755.1761.7660.00
13.0015.0017.0017.0014.0019.0021.0021.0016.0014.0020.0015.0017.0016.0021.0015.00
1.005.006.001.00-1.002.004.004.00-1.00-1.002.00–2.00––-3.00
-200.00400.0020.00-83.33-200.00-300.00100.00–-125.00–-300.00–––––
––––––––0.20–––––––
12.3413.2813.5913.3613.4213.6513.8313.8913.9614.1314.19140.61139.76117.40135.41132.81
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bio View generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bio View retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bio View's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bio View has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bio View's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bio View stock margins

The Bio View margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio View. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio View.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
59.71 %
-5.09 %
-4.51 %
Jan 1, 2018
58.39 %
-6.98 %
-7.33 %
Jan 1, 2019
56.63 %
10.12 %
7.06 %
Jan 1, 2020
60.80 %
5.52 %
3.41 %
Jan 1, 2021
57.63 %
10.31 %
7.16 %
Jan 1, 2022
57.20 %
6.74 %
2.01 %
Jan 1, 2023
61.48 %
3.70 %
1.10 %
Jan 1, 2024
60.65 %
-9.65 %
-12.27 %

Bio View Stock Revenue, EBIT, Earnings per Share

The Bio View earnings per share therefore indicates how much revenue Bio View has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
1.99 ILS
-0.10 ILS
-0.09 ILS
Jan 1, 2018
1.79 ILS
-0.12 ILS
-0.13 ILS
Jan 1, 2019
2.52 ILS
0.26 ILS
0.18 ILS
Jan 1, 2020
0.18 ILS
0.01 ILS
0.01 ILS
Jan 1, 2021
0.22 ILS
0.02 ILS
0.02 ILS
Jan 1, 2022
0.25 ILS
0.02 ILS
0.01 ILS
Jan 1, 2023
0.26 ILS
0.01 ILS
0.00 ILS
Jan 1, 2024
0.19 ILS
-0.02 ILS
-0.02 ILS

Bio View business model & stock analysis

Bio View Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bio View historical P/E ratio, EBIT multiple, and P/S ratio

Bio View annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bio View shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
13.96 M Stocks
Jan 1, 2018
14.13 M Stocks
Jan 1, 2019
14.19 M Stocks
Jan 1, 2020
140.61 M Stocks
Jan 1, 2021
139.76 M Stocks
Jan 1, 2022
117.40 M Stocks
Jan 1, 2023
135.41 M Stocks
Jan 1, 2024
132.81 M Stocks

Bio View stock splits

In Bio View's history, there have been no stock splits.

Bio View Dividend History

1 years of dividend payments

YearAnnual DividendYoY ChangePayments
20170.20ILS—1×

Bio View dividend payout ratio

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2017
-22.30 %
Jan 1, 2018
0.00 %
Jan 1, 2019
0.00 %
Jan 1, 2020
0.00 %
Jan 1, 2021
0.00 %
Jan 1, 2022
0.00 %
Jan 1, 2023
0.00 %
Jan 1, 2024
0.00 %
Price targets and forecasts for Bio View are not yet available.

Bio View shareholder structure

% Name
19.96635%
Gill (Emmanuel)
Gill (Emmanuel)
10.31636%
Chen (Shir)
Chen (Shir)
9.90878%
Hagai (Avner)
Hagai (Avner)
7.47433%
Rappaport (Sondra)
Rappaport (Sondra)
6.57761%
Ayalon Mutual Funds Ltd
Ayalon Mutual Funds Ltd
0.34391%
Gidonian (Yossef)
Gidonian (Yossef)

Bio View Executives and Management Board

DK

Mr. David Kutas

(56)

President of Bio View (USA) Inc

Compensation916,000.00 ILS
AS

Dr. Alan Schwebel

(60)

Chief Executive Officer, Director

Compensation771,000.00 ILS
YH

Mr. Yuval Harari

(54)

Executive Vice President · since 2000

Compensation634,000.00 ILS
EG

Emmanuel Gill

(76)

Chairman of the Board · since 2000

YK

Ms. Yulia Oroniuk Kapon

(37)

Chief Financial Officer

Frequently asked questions about Bio View

Converted at the current exchange rate, the Bio View share trades at 26.24 EUR (90.30 ILS).

All fundamentals and in-depth analysis of Bio View

Our stock analysis for Bio View stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio View. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bio View Stock
Bio View Revenue→
Bio View Stock
Bio View Net Income→
Bio View Stock
Bio View P/E→
Bio View Stock
Bio View P/S→
Bio View Stock
Bio View EBIT→
Bio View Stock
Bio View Dividend→
Bio View Stock
Bio View Directors Dealings→
Bio View Stock
Bio View Stocks→
Bio View Stock
Bio View Market capitalization→
Bio View Stock
Bio View Debt→
Bio View Stock
Bio View Liabilities→
Bio View Stock
Bio View Equity→
Bio View Stock
Bio View AAQS→
Bio View Stock
Bio View Employees→
Bio View Stock
Bio View ROE→
Bio View Stock
Bio View ROA→
Bio View Stock
Bio View ROCE→
Bio View Stock
Bio View News→
Bio View Stock
Bio View Analyst Price Targets→

Health Stocks

Bio-FD&C CoBio Solution CoBio-TechneBio Rad LaboratoriesBio-Thera SolutionsBio Preventive MedicineBio-Works TechnologiesBio Plus CobioAffinity TechnologiesBio Path HoldingsBIOAGE LabsBio Green Med SolutionAll Stocks A–Z →